We're heading to ICCAT 2026! We are thrilled to announce that our research paper, "A Multimodal AI Digital Twin Architecture for Simulating Pharmacokinetics in Phase 0 Clinical Trials," has been officially accepted for publication and presentation at the upcoming ICCAT 2026 conference. Why It Matters At OSCOWL ai, we're focused on accelerating the pace of drug discovery. Our newly accepted research details a groundbreaking approach using Multimodal AI to build Digital Twins . By accurately simulating how drugs move through the body during Phase 0 (microdosing) trials, this architecture allows researchers to: Safely predict optimal drug dosages earlier than ever. Minimize risks and resource drain in early-stage human testing. Drastically cut down the time and cost of pharmaceutical R&D. Looking Ahead This is a massive milestone for our team and our mission to merge advanced AI with cutting-edge health tech. We look forward to sharing our vision and connecting wit...
What we have today